guilherme henrique espíndola efeitos adversos dos ... - UFSC

More documents

Recommendations

Info

SUMMARY1. Introduction: the toxicity of antiretroviral drugs is one of the most importantfactors about treatment, adherence and consequently, in their efficacy to changeHIV-infected patients morbility and mortality.2. Objective: the aim this study was verify if there is any direct relation betweenantiretroviral drugs use and the values of laboratorial parameters in anambulatorial pediatric population.3. Methods: we revised 80 records of children attended in a Serviço de AssitênciaSpecialized of Hospital Infantil Joana de Gusmão (Florianópolis, SC). Childrenwere classified by age, treatment scheme and time of treatment, and thefollowing laboratorial data were evaluated: cholesterol, triglycerides, amylase,asparte and alanine aminotransferasis, glycemic levels and hemoglobin.4. Results: the majority of children was male (55%). The mean of age was 9,06years old. 68,75% of those infants have been treated with ARVT for five yearsor more time. About clinical and immunological classification the mostrepresentative group was A2 with 28,75%. The group that used ddI hadtriglyceride level than the group that not used it. Between the groups with andwithout AZT use, the total cholesterol and triglycerides levels were higher in thegroup with the drug. The infants that have used d4T had a chance 11 timeshigher that present elevated levels of total cholesterol than the group that haveno use it. The children with ARVT containing PI had a chance 2,94 times higherthat have elevated total cholesterol blood levels than the group that have no useit.5. Conclusions: There was no significative difference for none laboratorialparameter among the groups with PI versus NNRTI, with PI versus without PIand with d4T versus without d4T.
GLOSSÁRIO1. HIV – Human Immunodeficiency Virus - Vírus da ImunodeficiênciaHumana2. ARV – Antiretroviral3. TARV – Terapia Antiretroviral4. AZT – Zidovudina5. ddI – Didanosina6. IP – Inibidor de Protease7. ITRN – Inibidor de Transcriptase Reversa Análogo de Nucleosídeos8. ITRNN - Inibidor de Transcriptase Reversa Não-Análogo deNucleosídeos9. d4T – Estavudina10. HAART – Highly active antiretroviral therapy – terapia antiretroviral dealta atividade11. CDC – Central and Control Disease12. PENTA – Pediatric European Network for Treatment of AIDS13. FDA - Food and drug administration14. RTV – Ritonavir15. NFV – Nelfinavir
Page 1 and 2: GUILHERME HENRIQUE ESPÍNDOLAEFEITO
Page 3 and 4: Espíndola, Guilherme HenriqueEfeit
Page 5 and 6: AGRADECIMENTOSMeus sinceros agradec
Page 7: AZT na TARV utilizada. As crianças
Page 11 and 12: 1. INTRODUÇÃONo decorrer da déca
Page 13 and 14: Enquanto o desenvolvimento de novos
Page 15 and 16: 2. OBJETIVOO objetivo do presente e
Page 17 and 18: c) Recusa dos responsáveis na part
Page 19 and 20: 4. RESULTADOSNo período compreendi
Page 21 and 22: 4.1 Níveis séricos de Colesterol
Page 23 and 24: 44,6168. Esta comparação não dem
Page 25 and 26: Os valores médios de amilase com T
Page 27 and 28: 39,1726. As crianças que não usav
Page 29 and 30: Tabela 6 - Média de valores bioqu
Page 31 and 32: Tabela 8 - Comparação entre Níve
Page 33 and 34: DISCUSSÃOUma vez não havendo uma
Page 35 and 36: drogas da classe dos ITRN. Vinte e
Page 37 and 38: também infectados pelo HIV pode fa
Page 39 and 40: esquema da TARV, obtiveram um valor
Page 41 and 42: REFERÊNCIAS BIBLIOGRÁFICAS1. Prog
Page 43 and 44: 25. Cheseaux JJ, Jotterand V, Aebi

guilherme henrique espíndola efeitos adversos dos ... - UFSC

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?